Reduction of Mortality and Major Adverse Cardiovascular Events (MACE) in Men with Hypogonadism and Type 2 Diabetes (T2DM) Receiving Long-Term Treatment with Injectable Testosterone Undecanoate (TU): Ten-Year Data from a Urological Registry Study

被引：0

|

作者：

Haider, Karim S.

Haider, Ahmad

Saad, Farid

机构：

来源：

DIABETES | 2019年 / 68卷

关键词：

D O I：

10.2337/db19-1123-P

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1123-P

引用

收藏

页数：2

相关论文

共 50 条

[41] Long-term treatment with testosterone can lead to remission of T2D in hypogonadal men with type 2 diabetes (T2D): results of a urological registry study
Saad, Farid
Haider, Ahmad
Haider, Karim Sultan
WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (SUPPL 4) : 256 - 257
[42] TESTOSTERONE TREATMENT PREVENTS PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES (T2DM) IN 303 HYPOGONADAL MEN: 14-YEAR REAL-LIFE DATA FROM A REGISTRY
Yassin, Aksam
Mahdi, Mohammed
Alwani, Mustafa
Talib, Riad
Jaber, Abdel Rahman
Alrumaihi, Khalid
JOURNAL OF UROLOGY, 2020, 203 : E1175 - E1175
[43] Progression from Prediabetes to Type 2 Diabetes (T2DM) in 303 Hypogonadal Men With and Without Testosterone Treatment-Eight-Year Real-Life Data from a Registry
Saad, Farid
Haider, Ahmad
Haider, Karim S.
DIABETES, 2018, 67
[44] Testosterone Treatment Improves Glycemic Control and Leads to Remission in 56.8% of Patients with Hypogonadism and Type 2 Diabetes (T2DM) : Update of Real-World Data from a Registry Study
Haider, Ahmad
Haider, Karim S.
Saad, Farid
DIABETES, 2022, 71
[45] Long-term treatment with testosterone in hypogonadal men with type 2 diabetes (T2D) improves surrogate parameters of renal function: results of a urological registry study
Saad, Farid
Haider, Karim Sultan
Haider, Ahmad
WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (SUPPL 4) : 257 - 257
[46] Long-Term Testosterone Treatment Improves Estimated Glomerular Filtration Rate (eGFR) in Men with Hypogonadism and Type 2 Diabetes Mellitus: Update of Registry Data
Haider, Karim S.
Haider, Ahmad
Saad, Farid
DIABETES, 2022, 71
[47] Lipid Pattern in Men with Hypogonadism and Type 2 Diabetes Receiving Long-Term Testosterone Treatment Compared with an Untreated Control Group: Update of a Real-World Registry
Saad, Farid
Haider, Karim S.
Haider, Ahmad
DIABETES, 2022, 71
[48] Reduction of Weight and HbA1c in obese hypogonadal Men with Type 2 Diabetes under Long-term Treatment with Testosterone Undecanoate (TU) in Comparison to an untreated Control Group
Saad, Farid
Haider, Ahmad
Haider, Karim Sultan
WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (19-20) : 738 - 738
[49] Treatment with Testosterone Undecanoate Injections (TU) Up to 12 Years Improves Glycemic Control in Patients with Hypogonadism and Type 2 Diabetes (T2DM): Update of Real-World Data with 3,149 Patient-Years
Saad, Farid
Haider, Karim S.
Haider, Ahmad
DIABETES, 2021, 70
[50] Effects of long-term therapy with testosterone on liver metabolism over 11 years in men with hypogonadism and type 2 diabetes: real-world data from a registry study
Wissinger, U.
Haider, K. S.
Haider, A.
Doros, G.
Traish, A.
Saad, F.
DIABETOLOGIA, 2020, 63 (SUPPL 1) : S418 - S418

← 1 2 3 4 5 →